|
2023 Journal Article Accuracy of oncologists' estimates of expected survival time in advanced cancerNahm, Sharon H., Martin, Andrew J., Clayton, Josephine M., Grimison, Peter, Moth, Erin B., Pavlakis, Nick, Sjoquist, Katrin, Smith-Uffen, Megan E. S., Tognela, Annette, Vasista, Anuradha, Stockler, Martin R. and Kiely, Belinda E. (2023). Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectrum, 7 (6) pkad094. doi: 10.1093/jncics/pkad094 |
|
2023 Journal Article SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancerJefford, Michael, Emery, Jon D., James Martin, Andrew, De Abreu Lourenco, Richard, Lisy, Karolina, Grunfeld, Eva, Mohamed, Mustafa Abdi, King, Dorothy, Tebbutt, Niall C., Lee, Margaret, Mehrnejad, Ashkan, Burgess, Adele, Marker, Julie, Eggins, Renee, Carrello, Joseph, Thomas, Hayley and Schofield, Penelope (2023). SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancer. eClinicalMedicine, 66 102346, 1-11. doi: 10.1016/j.eclinm.2023.102346 |
|
2023 Conference Publication Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)Gedye, C., Harris, C. A., Stockler, M. R., Morris, M., Ferguson, T., Goh, J. C. H., Martin, A., Underhill, C. R., Pook, D., Krieger, L. E. M., Kichenadasse, G., Joshi, A. J., Subramaniam, S., Zebic, D. S., Zhang, A., Joshua, A. M., Toner, G. C., Vasey, P. A., Prithviraj, P. and Davis, I. D. (2023). Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.1116 |
|
2023 Conference Publication Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)Horvath, L. G., Davis, I. D., Martin, A., Zielinski, R., Thomson, A., Tan, T. H., Sandhu, S. K., Reaume, M. N., Pook, D., Parnis, F., North, S., Marx, G. M., McCaffrey, J. A., McDermott, R. S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K. N. N., Stockler, M. R. and Sweeney, C. (2023). Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.2742 |
|
2023 Conference Publication Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Weickhardt, A. J., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C. H., Pattison, D. A., Tan, H., Kirkwood, I. D., Sandhu, S. K., Nguyen, A., Gedye, C., Rutherford, N., Hofman, M., Martin, A., Stockler, M. R. and Davis, I. D. (2023). Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.10.086 |
|
2023 Journal Article Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancerSjoquist, Katrin M., Martin, Andrew, Pavlakis, Nick, Goldstein, David, Tsobanis, Eric, Moses, Daniel, Maher, Richard, Hague, Wendy, Gebski, Val, Stockler, Martin R. and Simes, R. John (2023). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. Journal of Cancer Research and Clinical Oncology, 149 (8), 4959-4965. doi: 10.1007/s00432-022-04404-4 |
|
2023 Conference Publication Effects of [<SUP>177</SUP>Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysisSoon, Yu Yang, Marschner, Ian, Hofman, Michael S., Emmett, Louise, Davis, Ian D., Stockler, Martin R. and Martin, Andrew James (2023). Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2023. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2023 Conference Publication Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102 |
|
2023 Conference Publication SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivorsJefford, Michael, Emery, Jon D., Martin, Andrew James, Lourenco, Richard De Abreu, Lisy, Karolina, Mohamed, Mustafa Abdi, King, Dorothy, Tebbutt, Niall C., Lee, Margaret, Mehrnejad, Ashkan, Burgess, Adele, Marker, Julie, Eggins, Renee, Carrello, Joseph, Thomas, Hayley and Schofield, Penelope (2023). SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2023. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2023 Journal Article Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialSweeney, Christopher J, Martin, Andrew J, Stockler, Martin R, Begbie, Stephen, Cheung, Leanna, Chi, Kim N, Chowdhury, Simon, Frydenberg, Mark, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, Marx, Gavin, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A, Parnis, Francis, Parulekar, Wendy, Pook, David W, Reaume, Martin Neil, Sandhu, Shahneen K, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G, Winter, Diana, Yip, Sonia, Zhang, Alison Y ... Thomas, Carys (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (4), 323-334. doi: 10.1016/S1470-2045(23)00063-3 |
|
2023 Journal Article Nicotinamide for skin-cancer chemoprevention in transplant recipientsAllen, Nicholas C., Martin, Andrew J., Snaidr, Victoria A., Eggins, Renee, Chong, Alvin H., Fernandéz-Peñas, Pablo, Gin, Douglas, Sidhu, Shireen, Paddon, Vanessa L., Banney, Leith A., Lim, Adrian, Upjohn, Edward, Schaider, Helmut, Ganhewa, Aparna D., Nguyen, Jennifer, Mckenzie, Catriona A., Prakash, Saurabh, Mclean, Catriona, Lochhead, Alistair, Ibbetson, Jan, Dettrick, Andrew, Landgren, Anthony, Allnutt, Katherine J., Allison, Clare, Davenport, Rachael B., Mumford, Blake P., Wong, Brittany, Stagg, Brendan, Tedman, Alexander ... Damian, Diona L. (2023). Nicotinamide for skin-cancer chemoprevention in transplant recipients. New England Journal of Medicine, 388 (9), 804-812. doi: 10.1056/NEJMoa2203086 |
|
2023 Journal Article INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)Lam, Lyn Ley, Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin M., Martin, Andrew J., Yip, Sonia, Kang, Yoon-Koo, Bang, Yung-Jue, Chen, Li-Tzong, Moehler, Markus, Bekaii-Saab, Tanios, Alcindor, Thierry, O’Callaghan, Christopher J., Tebbutt, Niall C., Hague, Wendy, Chan, Howard, Rha, Sun Young, Lee, Keun-Wook, Gebski, Val, Jaworski, Anthony, Zalcberg, John, Price, Timothy, Simes, John and Goldstein, David (2023). INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer, 23 (1) 180, 1-12. doi: 10.1186/s12885-023-10642-7 |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431 |
|
2023 Conference Publication Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Weickhardt, Andrew James, Lee, Sze Ting, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D. and Emmett, Louise (2023). Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271 |
|
2023 Conference Publication P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Ben Tran,, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Journal Article Evaluation of 177Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)Pathmanandavel, Sarennya, Crumbaker, Megan, Ho, Bao, Yam, Andrew O., Wilson, Peter, Niman, Remy, Ayers, Maria, Sharma, Shikha, Hickey, Adam, Eu, Peter, Stockler, Martin, Martin, Andrew J., Joshua, Anthony M., Nguyen, Andrew and Emmett, Louise (2023). Evaluation of 177Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN). Journal of Nuclear Medicine, 64 (2), 221-226. doi: 10.2967/jnumed.122.264398 |
|
2023 Journal Article Nicotinamide for Skin-Cancer Chemoprevention in TransplantationSchmults, Chrysalyne D., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily, Trepanowski, Nicole, Kim, Daniel Y., Hartman, Rebecca I., Allen, Nicholas C., Martin, Andrew J. and Damian, Diona L. (2023). Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. New England Journal of Medicine, 388 (26), 2493-2495. doi: 10.1056/NEJMc2303841 |
